{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:45:07Z","timestamp":1792827907809,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"\n Importance<\/jats:title>\n Observational studies of survivors of breast cancer and prospective trials of aspirin for cardiovascular disease suggest improved breast cancer survival among aspirin users, but prospective studies of aspirin to prevent breast cancer recurrence are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether aspirin decreases the risk of invasive cancer events among survivors of breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A011502, a phase 3, randomized, placebo-controlled, double-blind trial conducted in the United States and Canada with 3020 participants who had high-risk nonmetastatic breast cancer, enrolled participants from 534 sites from January 6, 2017, through December 4, 2020, with follow-up to March 4, 2023.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized (stratified for hormone receptor status [positive vs negative], body mass index [\u226430 vs &amp;gt;30], stage II vs III, and time since diagnosis [&amp;lt;18 vs \u226518 months]) to receive 300 mg of aspirin (n\u2009=\u20091510) or placebo once daily (n\u2009=\u20091510) for 5 years.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was invasive disease\u2013free survival. Overall survival was a key secondary outcome.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 3020 participants were randomized when the data and safety monitoring committee recommended suspending the study at the first interim analysis because the hazard ratio had crossed the prespecified futility bound. By median follow-up of 33.8 months (range, 0.1-72.6 months), 253 invasive disease\u2013free survival events were observed (141 in the aspirin group and 112 in the placebo group), yielding a hazard ratio of 1.27 (95% CI, 0.99-1.63;\n P<\/jats:italic>\n \u2009=\u2009.06). All invasive disease\u2013free survival events, including death, invasive progression (both distant and locoregional), and new primary events, were numerically higher in the aspirin group, although the differences were not statistically significant. There was no difference in overall survival (hazard ratio, 1.19; 95% CI, 0.82-1.72). Rates of grades 3 and 4 adverse events were similar in both groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n Among participants with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02927249<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2024.4840","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T11:32:56Z","timestamp":1714390376000},"page":"1714","source":"Crossref","is-referenced-by-count":34,"title":["Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer"],"prefix":"10.1001","volume":"331","author":[{"given":"Wendy Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla V.","family":"Ballman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olwen M.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick M.","family":"Briccetti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Irvin","sequence":"additional","affiliation":[{"name":"Bon Secours Cancer Institute, Richmond, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Symington","sequence":"additional","affiliation":[{"name":"Memorial Hospital of Sweetwater County, Rock Springs, Wyoming"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kala","family":"Visvanathan","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Openshaw","sequence":"additional","affiliation":[{"name":"Cape Cod Hospital, Hyannis, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[{"name":"UNC Lineberger Cancer Center, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle D.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"joi240044r1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-017-0605-6","article-title":"Role of aspirin in breast cancer survival.","volume":"19","author":"Chen","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"9826","key":"joi240044r2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"joi240044r3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.","volume":"159","author":"Cook","year":"2013","journal-title":"Ann Intern Med"},{"issue":"23","key":"joi240044r4","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1182\/blood.2019003977","article-title":"Aspirin and antiplatelet treatments in cancer.","volume":"137","author":"Tao","year":"2021","journal-title":"Blood"},{"issue":"5","key":"joi240044r5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","article-title":"Targeting cancer-promoting inflammation\u2014have anti-inflammatory therapies come of age?","volume":"18","author":"Hou","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"joi240044r6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"joi240044r7","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","article-title":"Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node\u2013positive and high-risk lymph node\u2013negative breast cancer (E5103).","volume":"36","author":"Miller","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"joi240044r8","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/sim.v9:12","article-title":"Group sequential designs using a family of type I error probability spending functions.","volume":"9","author":"Hwang","year":"1990","journal-title":"Stat Med"},{"issue":"23","key":"joi240044r9","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"joi240044r10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2337\/dc08-1206","article-title":"A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women.","volume":"32","author":"Pradhan","year":"2009","journal-title":"Diabetes Care"},{"issue":"16","key":"joi240044r11","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.2022.3337","article-title":"Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"327","author":"Guirguis-Blake","year":"2022","journal-title":"JAMA"},{"issue":"16","key":"joi240044r12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"joi240044r13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of aspirin on cancer incidence and mortality in older adults.","volume":"113","author":"McNeil","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"joi240044r14","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2337\/dc18-0368","article-title":"Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial.","volume":"41","author":"Okada","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"joi240044r15","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00432-019-02932-0","article-title":"Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials.","volume":"145","author":"Haykal","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"joi240044r16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10147-021-01913-z","article-title":"Aging, cancer, and antitumor immunity.","volume":"27","author":"Ikeda","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"joi240044r17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.v72.6","article-title":"Breast cancer statistics, 2022.","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"joi240044r18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw322","article-title":"Colorectal cancer incidence patterns in the United States, 1974-2013.","volume":"109","author":"Siegel","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"10240","key":"joi240044r19","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"joi240044r20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"joi240044r21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences.","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"5","key":"joi240044r22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention.","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"joi240044r23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cct.2016.10.004","article-title":"ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.","volume":"51","author":"Coyle","year":"2016","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"joi240044r24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO clinical practice guideline focused update.","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"joi240044r25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.7326\/M19-0953","article-title":"Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey.","volume":"171","author":"O\u2019Brien","year":"2019","journal-title":"Ann Intern Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2818110\/jama_chen_2024_oi_240044_1716416461.34153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T14:08:06Z","timestamp":1716905286000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2818110"}},"subtitle":["The Alliance A011502 Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":25,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.4840","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}